EPO enhances the protective effects of MSCs in experimental hyperoxia-induced neonatal mice by promoting angiogenesis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Print Cited Medium: Internet ISSN: 1945-4589 (Electronic) Linking ISSN: 19454589 NLM ISO Abbreviation: Aging (Albany NY) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Albany, NY : Impact Journals, LLC
    • Subject Terms:
      Bronchopulmonary Dysplasia/*metabolism ; Endothelium, Vascular/*drug effects ; Erythropoietin/*pharmacology ; Lung/*drug effects ; Mesenchymal Stem Cells/*drug effects ; Neovascularization, Physiologic/*drug effects; Animals ; Animals, Newborn ; Apoptosis/drug effects ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Chemokine CXCL12/metabolism ; Disease Models, Animal ; Endothelium, Vascular/metabolism ; Lung/metabolism ; Mesenchymal Stem Cells/metabolism ; Mice ; Receptors, CXCR4/metabolism ; Vascular Endothelial Growth Factor A/metabolism
    • Abstract:
      Bronchopulmonary dysplasia (BPD) is the most common type of chronic lung disease in infancy; however, there is no effective treatment for it. In the present study, a neonatal mouse BPD model was established by continuous exposure to high oxygen (HO) levels. Mice were divided randomly into 5 groups: control, BPD, EPO, MSCs, and MSCs+EPO. At 2 weeks post-treatment, vessel density and the expression levels of endothelial growth factor (VEGF), stromal cell-derived factor-1 (SDF-1), and its receptor C-X-C chemokine receptor type 4 (CXCR4) were significantly increased in the MSC+EPO group compared with the EPO or MSCs group alone; moreover, EPO significantly enhanced MSCs proliferation, migration, and anti-apoptosis ability in vitro. Furthermore, the MSCs could differentiate into cells that were positive for the type II alveolar epithelial cell (AECII)-specific marker surfactant protein-C, but not positive for the AECI-specific marker aquaporin 5. Our present results suggested that MSCs in combination with EPO could significantly attenuate lung injury in a neonatal mouse model of BPD. The mechanism may be by the indirect promotion of angiogenesis, which may involve the SDF-1/CXCR4 axis.
    • References:
      Am J Physiol Lung Cell Mol Physiol. 2002 Sep;283(3):L555-62. (PMID: 12169575)
      Am J Physiol Lung Cell Mol Physiol. 2012 May 1;302(9):L829-37. (PMID: 22328358)
      J Surg Res. 2009 Jul;155(1):104-10. (PMID: 19285686)
      Am J Respir Cell Mol Biol. 2016 Mar;54(3):319-30. (PMID: 26203800)
      J Pathol. 2002 Jul;197(4):527-35. (PMID: 12115868)
      Am J Respir Crit Care Med. 2009 Dec 1;180(11):1039-41. (PMID: 19923401)
      Biomaterials. 2013 Dec;34(37):9393-400. (PMID: 24054847)
      Adv Biochem Eng Biotechnol. 2013;130:105-29. (PMID: 22772131)
      Am J Respir Cell Mol Biol. 1999 Jan;20(1):14-23. (PMID: 9870913)
      Stem Cells. 2011 Jun;29(6):913-9. (PMID: 21506195)
      Am J Respir Cell Mol Biol. 2005 Aug;33(2):145-52. (PMID: 15891110)
      Physiol Rev. 1992 Apr;72(2):449-89. (PMID: 1557429)
      Am J Respir Crit Care Med. 2006 Jan 15;173(2):204-11. (PMID: 16210670)
      Eur Rev Med Pharmacol Sci. 2016 Mar;20(5):899-905. (PMID: 27010148)
      Am J Physiol Lung Cell Mol Physiol. 2002 Apr;282(4):L811-23. (PMID: 11880308)
      Adv Exp Med Biol. 2010;661:323-35. (PMID: 20204740)
      Neonatology. 2012;102(4):287-92. (PMID: 22922736)
      Am J Respir Crit Care Med. 2018 Jan 1;197(1):104-116. (PMID: 28853608)
      Proc Am Thorac Soc. 2006 May;3(3):193-207. (PMID: 16636086)
      J Cell Sci. 2004 Nov 1;117(Pt 23):5655-64. (PMID: 15494370)
      Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1755-6. (PMID: 11734417)
      Food Chem Toxicol. 2018 Apr;114:23-33. (PMID: 29432836)
      J Cell Biochem. 2018 Jan;119(1):1008-1016. (PMID: 28686347)
      Am J Respir Crit Care Med. 2009 Dec 1;180(11):1131-42. (PMID: 19713449)
      Pediatr Transplant. 2012 Sep;16(6):589-98. (PMID: 22738184)
      Stem Cells. 2007 Nov;25(11):2896-902. (PMID: 17901396)
      PLoS One. 2009;4(3):e4891. (PMID: 19305493)
      Neonatology. 2007;91(4):291-7. (PMID: 17575472)
      Front Biosci. 2003 May 01;8:e370-80. (PMID: 12700058)
      Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):676-684. (PMID: 29233725)
      J Thromb Haemost. 2015 Mar;13(3):465-76. (PMID: 25495701)
      J Am Coll Cardiol. 2006 Dec 5;48(11):2161-7. (PMID: 17161240)
      Am J Respir Crit Care Med. 2009 Dec 1;180(11):1122-30. (PMID: 19713447)
      Biomed Res Int. 2013;2013:561098. (PMID: 24381939)
      Blood. 1991 Jun 15;77(12):2583-90. (PMID: 1646044)
      Eur J Neurosci. 2007 Jul;26(1):90-100. (PMID: 17614942)
      Respir Res. 2015 Jan 16;16:4. (PMID: 25591994)
      Pharmacol Ther. 2011 Jan;129(1):97-108. (PMID: 20965212)
      Am J Physiol Lung Cell Mol Physiol. 2013 Dec;305(12):L893-905. (PMID: 24213917)
      Mol Med Rep. 2016 Aug;14(2):1302-8. (PMID: 27279073)
      J Physiol. 2014 May 1;592(9):1993-2002. (PMID: 24591575)
    • Contributed Indexing:
      Keywords: BPD; EPO; MSCs; SDF-1/CXCR4; angiogenesis
    • Accession Number:
      0 (CXCR4 protein, mouse)
      0 (Chemokine CXCL12)
      0 (Receptors, CXCR4)
      0 (Vascular Endothelial Growth Factor A)
      11096-26-7 (Erythropoietin)
    • Publication Date:
      Date Created: 20190430 Date Completed: 20200521 Latest Revision: 20200521
    • Publication Date:
      20250114
    • Accession Number:
      PMC6519997
    • Accession Number:
      10.18632/aging.101937
    • Accession Number:
      31035257